Clinical Evaluation of the Efficacy of Dietary Sulforaphane on Male Fatty Liver Patients with Liver Dysfunctio
- Conditions
- Abnormality of liver function
- Registration Number
- JPRN-UMIN000012855
- Lead Sponsor
- Tokai University School of Medicine
- Brief Summary
Dietary supplementation with sulforaphane precursor glucoraphanin for 2 months significantly decreased serum levels of liver function markers, ALT and g-GTP, and an established oxidative stress marker, urinary level of 8-OHdG. The reduction of urinary 8-OHdG was significantly correlated with decreased levels of both ALT and g-GTP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 40
Not provided
We will exclude outpatients 1) with serious liver diseases and suspected acute liver failure. 2) with viral hepatitis 3) with serious heart problem 4) with renal dysfunction (serum creatinine > 2.0 mg/dL) 5) with bile duct cancer 6) without capacity of self- management of drug therapy 7) with serious diseases in their life and then judged unsuitable for this study 8) with risk of allergy 9) with suspected infectious diseases 10) who participated in other clinical trials within 2 months. 11) who habitually consume higher amount of alcohol (> avg 60 g alcohol/day) 12) who are judged unsuitable for this study by principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method